{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:36:51Z","timestamp":1791387411702,"version":"4.3.3"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We studied clinical characteristics, appropriateness of initial antibiotic treatment, and other factors associated with day 30 mortality in patients with bacteremia caused by extended-spectrum-\u03b2-lactamase (ESBL)-producing bacteria in eight Dutch hospitals. Retrospectively, information was collected from 232 consecutive patients with ESBL bacteremia (due to\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            , and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacter cloacae<\/jats:named-content>\n            ) between 2008 and 2010. In this cohort (median age of 65 years; 24 patients were &lt;18 years of age), many had comorbidities, such as malignancy (34%) or recurrent urinary tract infection (UTI) (15%). One hundred forty episodes (60%) were nosocomial, 54 (23%) were otherwise health care associated, and 38 (16%) were community acquired. The most frequent sources of infection were UTI (42%) and intra-abdominal infection (28%). Appropriate therapy within 24 h after bacteremia onset was prescribed to 37% of all patients and to 54% of known ESBL carriers. The day 30 mortality rate was 20%. In a multivariable analysis, a Charlson comorbidity index of \u22653, an age of \u226575 years, intensive care unit (ICU) stay at bacteremia onset, a non-UTI bacteremia source, and presentation with severe sepsis, but not inappropriate therapy within &lt;24 h (adjusted odds ratio [OR], 1.53; 95% confidence interval [CI], 0.68 to 3.45), were associated with day 30 mortality. Further assessment of confounding and a stratified analysis for patients with UTI and non-UTI origins of infection did not reveal a statistically significant effect of inappropriate therapy on day 30 mortality, and these results were insensitive to the possible misclassification of patients who had received \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations or ceftazidime as initial treatment. In conclusion, ESBL bacteremia occurs mostly in patients with comorbidities requiring frequent hospitalization, and 84% of episodes were health care associated. Factors other than inappropriate therapy within &lt;24 h determined day 30 mortality.\n          <\/jats:p>","DOI":"10.1128\/aac.01523-12","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T03:39:22Z","timestamp":1366688362000},"page":"3092-3099","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Appropriateness of Empirical Treatment and Outcome in Bacteremia Caused by Extended-Spectrum-\u03b2-Lactamase-Producing Bacteria"],"prefix":"10.1128","volume":"57","author":[{"given":"Florine N. J.","family":"Frakking","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Rottier","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wendelien","family":"Dorigo-Zetsma","sequence":"additional","affiliation":[{"name":"Central Laboratory for Bacteriology and Serology, Tergooi Hospitals, Hilversum, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarne M.","family":"van Hattem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tergooi Hospitals, Hilversum, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette C.","family":"van Hees","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Gelre Hospitals, Apeldoorn, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A. J. W.","family":"Kluytmans","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Control, Amphia Hospital, Breda, the Netherlands"},{"name":"Department of Medical Microbiology and Infection Control, VU Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne P. M.","family":"Lutgens","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Control, Amphia Hospital, Breda, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven F. T.","family":"Thijsen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, Diakonessenhuis, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J. M.","family":"Vlaminckx","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Cohen Stuart","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurine A.","family":"Leverstein-van Hall","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"National Institute for Public Health and the Environment, Bilthoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03703.x"},{"key":"e_1_3_2_3_2","volume-title":"CLSI document M100-S20","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir793"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks065"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/11533040-000000000-00000"},{"key":"e_1_3_2_8_2","volume-title":"Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","year":"2011","unstructured":"European Centre for Disease Prevention and Control. 2011. Antimicrobial resistance surveillance in Europe 2010. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control, Stockholm, Sweden."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr453"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-5079-z"},{"key":"e_1_3_2_11_2","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Frakking FNJ","year":"2012","unstructured":"FrakkingFNJ RottierWC DorigoW Van HattemJ Van HeesBC KluytmansJAJW Dumont-LutgensS PrinsJM ThijsenSFT VerbonA VlaminckxBJ Cohen StuartJ Leverstein-van HallM BontenMJM. 2012. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis., London, United Kingdom, 3 April 2012, poster P1860."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-1-200401060-00008"},{"key":"e_1_3_2_14_2","volume-title":"CLSI document M100-S17","author":"CLSI","year":"2007","unstructured":"CLSI. 2007. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03739.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-10-200211190-00007"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199711000-00014"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/604713"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.17.1897"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.09.034"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_23_2","volume-title":"SWAB guidelines for antibacterial therapy of adult patients with sepsis","author":"Dutch Working Party on Antibiotic Policy","year":"2010","unstructured":"Dutch Working Party on Antibiotic Policy. 2010. SWAB guidelines for antibacterial therapy of adult patients with sepsis. SWAB, Amsterdam, the Netherlands."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00627-10"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.5.1615"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.146"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00063-08"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-06"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02353-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4574-4581.2004"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05753-11"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0201-x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2010.08.004"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00565-10"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn514"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2000.0862"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00044-07"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-11"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01523-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01523-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:32:25Z","timestamp":1645482745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01523-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/AAC.01523-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01523-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"2012-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}